| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 11 4128-4136, Copyright © 1996 by American Association of Immunologists
ARTICLES |
C Martinez, M Delgado, RP Gomariz and D Ganea
Department of Cellular Biology, Faculty of Biology, Complutense University, Madrid, Spain.
Vasoactive intestinal peptide (VIP), a neuropeptide present in the peptidergic innervation of lymphoid organs and expressed in thymocytes and peripheral lymphocytes has been previously reported to modulate cytokine expression in T lymphocytes. In this study, we investigated the effects of VIP and of the structurally related neuropeptide PACAP- 38 on the expression of IL-10 in murine lymphocyte cultures. Both neuropeptides inhibit IL-10 production by spleen cells or thymocytes activated via the TCR-associated CD3 complex in a similar dose-response manner. The inhibition is specific, presumably mediated through the VIP- R1, and maximum inhibitory levels are achieved within the first 5 to 15 min of exposure to VIP or PACAP-38. CD4+ T cells function as direct cellular targets for the two neuropeptides. The fact that VIP, PACAP- 38, and forskolin, all known cAMP inducers, also inhibit IL-10 production, suggests the participation of cAMP in signal transduction. VIP and PACAP-38 regulate transcriptional expression of IL-10, since IL- 10 steady state mRNA levels are significantly reduced by treatment with the two neuropeptides. These results expand the range of neuroendocrine- regulated cytokines and support the idea that neuropeptides such as VIP and PACAP, which are released or produced in the local lymphoid microenvironment and specifically modulate the expression of various cytokines, may participate in the intricate cytokine network controlling local immune responses.
This article has been cited by other articles:
|
|
 |
|
  D. Roosterman, T. Goerge, S. W. Schneider, N. W. Bunnett, and M. Steinhoff Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev, October 1, 2006; 86(4): 1309 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Voice, C. Grinninger, Y. Kong, Y. Bangale, S. Paul, and E. J. Goetzl Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice J. Immunol., January 1, 2003; 170(1): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. VOICE, G. DORSAM, H. LEE, Y. KONG, and E. J. GOETZL Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor FASEB J, November 1, 2001; 15(13): 2489 - 2496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Goetzl, J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide PNAS, October 31, 2001; (2001) 241503798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. He, R. Vemulapalli, A. Zeytun, and G. G. Schurig Induction of Specific Cytotoxic Lymphocytes in Mice Vaccinated with Brucella abortus RB51 Infect. Immun., September 1, 2001; 69(9): 5502 - 5508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Werner Status Asthmaticus in Children : A Review Chest, June 1, 2001; 119(6): 1913 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Sherwood, S. L. Krueckl, and J. E. McRory The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily Endocr. Rev., December 1, 2000; 21(6): 619 - 670. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.-W. M. Koh and J. A. Waschek Corneal Endothelial Cell Survival in Organ Cultures under Acute Oxidative Stress: Effect of VIP Invest. Ophthalmol. Vis. Sci., December 1, 2000; 41(13): 4085 - 4092. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-K. Kim, Y. Kan, D. Ganea, R. P. Hart, I. Gozes, and G. M. Jonakait Vasoactive Intestinal Peptide and Pituitary Adenylyl Cyclase-Activating Polypeptide Inhibit Tumor Necrosis Factor-alpha Production in Injured Spinal Cord and in Activated Microglia via a cAMP-Dependent Pathway J. Neurosci., May 15, 2000; 20(10): 3622 - 3630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. METWALI, A. M. BLUM, J. LI, D. E. ELLIOTT, and J. V. WEINSTOCK IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis FASEB J, May 1, 2000; 14(7): 948 - 954. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Delgado and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Interleukin-12 Transcription by Regulating Nuclear Factor kappa B and Ets Activation J. Biol. Chem., November 5, 1999; 274(45): 31930 - 31940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, J. Leceta, R. P. Gomariz, and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Stimulate the Induction of Th2 Responses by Up-Regulating B7.2 Expression J. Immunol., October 1, 1999; 163(7): 3629 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Prevent Inducible Nitric Oxide Synthase Transcription in Macrophages by Inhibiting NF-{kappa}B and IFN Regulatory Factor 1 Activation J. Immunol., April 15, 1999; 162(8): 4685 - 4696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, D. Pozo, C. Martinez, J. Leceta, J. R. Calvo, D. Ganea, and R. P. Gomariz Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Endotoxin-Induced TNF-{alpha} Production by Macrophages: In Vitro and In Vivo Studies J. Immunol., February 15, 1999; 162(4): 2358 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Enhance IL-10 Production by Murine Macrophages: In Vitro and In Vivo Studies J. Immunol., February 1, 1999; 162(3): 1707 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delgado, E. J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D. E. Brenneman, R. P. Gomariz, and D. Ganea Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor alpha Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun J. Biol. Chem., November 20, 1998; 273(47): 31427 - 31436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. P. Soares, R. G. Titus, C. B. Shoemaker, J. R. David, and M. Bozza The Vasoactive Peptide Maxadilan from Sand Fly Saliva Inhibits TNF-{alpha} and Induces IL-6 by Mouse Macrophages Through Interaction with the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Receptor J. Immunol., February 15, 1998; 160(4): 1811 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Goetzl, J. K. Voice, S. Shen, G. Dorsam, Y. Kong, K. M. West, C. F. Morrison, and A. J. Harmar Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide PNAS, November 20, 2001; 98(24): 13854 - 13859. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
